Morgan Stanley analyst Michael Ulz initiated coverage of Rocket Pharmaceuticals with an Overweight rating and $45 price target. The analyst says Rocket is a leader in gene therapy with a robust cardiovascular pipeline and a hematology pipeline providing near-term revenue. The pipeline is anchored by RP-A501 in Danon disease, which has blockbuster potential and is expected to enter a pivotal study in Q2, the analyst tells investors in a research note.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on RCKT:
- Rocket Pharmaceuticals adds RP-A601, PKP2-ACM to gene therapy portfolio
- Rocket Pharmaceuticals stock reaction looks ‘overdone,’ says BofA
- William Blair remains bullish on Rocket following FDA discussion commentary
- Rocket Pharmaceuticals weakness a buying opportunity, says UBS
- Rocket Pharmaceuticals provides update on registration path for RP-A501
